Should every transplant eligible NDMM patient receive a transplant?

Vaccinations in myeloma patients including for COVID-19

CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL

Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers

Real-world evidence of the use of carfilzomib among multiple myeloma patients across 10 European countries and Israel

Real-world evidence of the use of carfilzomib to refractory to lenalidomide patients

Real world management of multiple myeloma patients

Updates in geriatric medical oncology from SIOG meeting

Priorities of cancer research in Nepal

Management of infection risk to myeloma patients during the COVID pandemic

Lenalidomide combination for multiple myeloma

Mass spectrometry for the detection of minimal residual disease (MRD) in myeloma